Choline alfoscerate
- Generic Name
- Choline alfoscerate
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C8H20NO6P
- CAS Number
- 28319-77-9
- Unique Ingredient Identifier
- 60M22SGW66
- Background
A component of phosphatidylcholines (lecithins), in which the two hydroxy groups of glycerol are esterified with fatty acids. (From Stedman, 26th ed) It counteracts the effects of urea on enzymes and other macromolecules. [PubChem]
- Associated Conditions
- Affective Disorders, Cognitive Dysfunctions, Dementia, Multi-Infarct, Stroke, Traumatic Brain Injury (TBI)
- Associated Therapies
- -
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
Phase 4
Not yet recruiting
- Conditions
- Mild Cognitive Impairment
- Interventions
- Drug: PlaceboDrug: Choline Alfoscerate
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 418
- Registration Number
- NCT05041790
- Locations
- 🇰🇷
Asan Medical Center Institutional Review Board, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath